Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Loading history...
Latest & greatest articles for multiple sclerosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com
Trial of Fingolimod versus Interferon Beta-1a in Pediatric MultipleSclerosis. Treatment of patients younger than 18 years of age with multiplesclerosis has not been adequately examined in randomized trials. We compared fingolimod with interferon beta-1a in this population.In this phase 3 trial, we randomly assigned patients 10 to 17 years of age with relapsing multiplesclerosis in a 1:1 ratio to receive oral fingolimod at a dose of 0.5 mg per day (0.25 mg per day for patients with a body (...) ; relative difference, 82%; P<0.001). The key secondary end point of the annualized rate of new or newly enlarged lesions on T2-weighted magnetic resonance imaging (MRI) was 4.39 with fingolimod and 9.27 with interferon beta-1a (absolute difference, 4.88 lesions; relative difference, 53%; P<0.001). Adverse events, excluding relapses of multiplesclerosis, occurred in 88.8% of patients who received fingolimod and 95.3% of those who received interferon beta-1a. Serious adverse events occurred in 18
Phase 2 Trial of Ibudilast in Progressive MultipleSclerosis. There are limited treatments for progressive multiplesclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood-brain barrier, with potential salutary effects in progressive multiple sclerosis.We enrolled patients with primary or secondary progressive multiplesclerosis in a phase 2 randomized trial of oral ibudilast (≤100 mg (...) less brain-tissue loss with ibudilast over a period of 96 weeks. Adverse events with ibudilast included gastrointestinal symptoms, headache, and depression.In a phase 2 trial involving patients with progressive multiplesclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache, and depression. (Funded by the National Institute of Neurological Disorders and Stroke and others; NN102/SPRINT
Tumefactive multiplesclerosis masquerade as a central nervous system tumor: a case report Tumefactive multiplesclerosis is a demyelinating disorder that appears tumor-like on MRI. To most physicians, diagnosing tumefactive MS by applying clinical, radiological, or laboratory examination like Cerebrospinal fluid (CSF) analysis, can be challenging and ultimately biopsy is necessary to confirm the diagnosis.This paper reports a case of a 37-year-old woman who presented with progressive headache
Multiplesclerosis Top results for multiplesclerosis - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (...) (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for multiplesclerosis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many
Moderators of Treatment Outcomes After Telehealth Self-Management and Education in Adults With MultipleSclerosis: A Secondary Analysis of a Randomized Controlled Trial To examine moderators of treatment effects in a randomized controlled trial comparing a telehealth self-management intervention with a telehealth multiplesclerosis (MS) education intervention for fatigue, pain, and mood in adults with MS.Secondary analysis of a single-blind randomized controlled trial.Community.Adults with MS
Pharmacological treatment for memory disorder in multiplesclerosis Pharmacological treatment for memory disorder in multiplesclerosis - He, D - 2013 | Cochrane Library Cookies Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in . Trusted evidence. Informed decisions. Better health (...) Collections Pharmacological treatment for memory disorder in multiplesclerosis Cochrane Systematic Review - Intervention Version published: 17 December 2013 New search Collapse all Expand all Abstract available in Background This is an update of the Cochrane review "Pharmacologic treatment for memory disorder in multiplesclerosis" (first published in The Cochrane Library 2011, Issue 10). Multiplesclerosis (MS) is a chronic immune‐mediated, inflammatory, demyelinating, neurodegenerative disorder
Subcutaneous ofatumumab in patients with relapsing-remitting multiplesclerosis: The MIRROR study To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiplesclerosis (RMS).Patients (n = 232) were randomized to ofatumumab 3, 30, or 60 mg every 12 weeks, ofatumumab 60 mg every 4 weeks, or placebo for a 24-week treatment period, with a primary endpoint of cumulative number of new
Multiplesclerosis: a drug that should never have been authorised Prescrire IN ENGLISH - Spotlight ''Multiplesclerosis: a drug that should never have been authorised'', 1 July 2018 {1} {1} {1} | | > > > Multiplesclerosis: a drug that should never have been authorised Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Multiplesclerosis: a drug (...) that should never have been authorised In March 2018, after several deaths, daclizumab (Zinbryta°) was withdrawn from the market. The European Medicines Agency should never have authorised this drug. In patients with multiplesclerosis, interferon beta is the first-choice treatment, for want of a better option. Despite the severity of multiplesclerosis in some patients, there is no justification for exposing them to drugs such as alemtuzumab, natalizumab or teriflunomide, whose harm-benefit balance
Investigating the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiplesclerosis: a randomized controlled trial To evaluate the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis.It was a three-arm parallel randomized clinical trial study.Outpatient clinic.Patients with multiple sclerosis.Participants in the intervention groups completed an eight-week program consisting (...) obtained for the sexual function of mindfulness group were 19.5 ± 6.4, 26.9 ± 4.8, and 25.6 ± 4.5, respectively. Moreover, mean scores obtained for pelvic floor muscle exercise along with mindfulness were 19.6 ± 5.9, 25.3 ± 5.4, and 25 ± 4.8, respectively. There was no significant difference in their effects on sexual function ( P > 0.05).Mindfulness and pelvic floor muscle exercise do not have any significant impact upon sexual dysfunction of people with multiplesclerosis.
Multiplesclerosis Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading
Teriflunomide (Aubagio) - relapsing remitting multiplesclerosis (RRMS) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved
Comprehensive Systematic Review Summary: Disease-modifying Therapies for Adults with MultipleSclerosis 1 Practice guideline: Disease-modifying therapies for adults with multiplesclerosis Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Alexander Rae-Grant, MD 1 ; Gregory S. Day, MD, MSc 2 ; Ruth Ann Marrie, MD, PhD 3 ; Alejandro Rabinstein, MD 4 ; Bruce A.C. Cree, MD, PhD, MAS 5 ; Gary S. Gronseth, MD 6 ; Michael Haboubi (...) of MultipleSclerosis Centers, Hackensack, NJ 9. Department of Neuroscience, St. Luke’s University Health Network, Bethlehem, PA 10. Department of Neurology, School of Medicine, University of Virginia, Charlottesville 11. Consortium of MultipleSclerosis Centers, Hackensack, NJ, and Department of Neurology, School of Medicine, Wayne State University, Detroit, MI 12. Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles 13. Neurology Department, Southern
Preapproval and postapproval evidence on drugs for multiplesclerosis To review the evidence supporting the European Union marketing authorization of drugs for multiplesclerosis (MS) and assess how far postmarketing research addresses information gaps at the time of approval.Through its database, we identified drugs approved by the European Medicines Agency and gathered data on pivotal trials from the European Public Assessment Reports and corresponding publications. We searched Medline
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiplesclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology To develop recommendations for disease-modifying therapy (DMT) for multiplesclerosis (MS).A multidisciplinary panel developed DMT recommendations, integrating findings from a systematic review; followed an Institute of Medicine-compliant process to ensure transparency
Randomised controlled trial of a self-guided online fatigue intervention in multiplesclerosis Fatigue is a major disabling symptom in many chronic diseases including multiplesclerosis (MS), but treatment options are limited.Here, we tested the effectiveness of a self-guided , interactive, online fatigue management programme (ELEVIDA) based on principles of cognitive behavioural therapy (CBT) and related psychotherapeutic approaches (eg, mindfulness) for reducing fatigue in MS.Patients with MS
Chronic Cerebro-Spinal Venous Insufficiency in MultipleSclerosis: Is It the End? 29629362 2018 11 14 2288-7970 34 1 2018 Mar Vascular specialist international Vasc Specialist Int Chronic Cerebro-Spinal Venous Insufficiency in MultipleSclerosis: Is It the End? 16-18 10.5758/vsi.2018.34.1.16 Rasman Alessandro A Department of Political and Social Sciences, University of Trieste, Trieste, Italy. eng Journal Article 2018 03 31 Korea (South) Vasc Specialist Int 101633116 2288-7970 Conflict